Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Mar 9, 2026
Reporting period
Not applicable
Filed with the SEC
Mar 12, 2026
CEOGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references vesting of compensation awards
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001104659-26-026582
Filed / recorded
Mar 12, 2026, 1:15 AM UTC
Added to OQRO
Oct 8, 2026, 1:45 AM UTC
Parser
form4-xml-v2
Data quality
Verified: identifiers matched exactly
Issuer
Armata Pharmaceuticals, Inc.
Issuer CIK
921114
Ticker
ARMP
Reporting person
Deborah Birx
Relationship
Director, Officer
Officer title
Chief Executive Officer
Security
Stock Options (Right to Buy)
Table
Derivative (Table II)
Transaction date
Mar 9, 2026
Transaction code
A
Shares / units
421,226
Price per share
$0.00
Acquired / disposed
Acquired (A)
Shares owned after
421,226
Ownership form
Direct
Amendment
No
Footnotes from the filing
Twenty-five percent (25%) of the Stock Options shall vest on March 9th of each of 2027, 2028, 2029, and 2030, in each case subject to continuous service through the applicable vesting date.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.